APA (7th ed.) Citation

Iurlo, A., Cattaneo, D., Consonni, D., Castagnetti, F., Miggiano, M. C., Binotto, G., . . . Breccia, M. (2023). Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study. Frontiers in pharmacology, 14, 1154377. https://doi.org/10.3389/fphar.2023.1154377

Chicago Style (17th ed.) Citation

Iurlo, A., et al. "Treatment Discontinuation Following Low-dose TKIs in 248 Chronic Myeloid Leukemia Patients: Updated Results from a Campus CML Real-life Study." Frontiers in Pharmacology 14 (2023): 1154377. https://doi.org/10.3389/fphar.2023.1154377.

MLA (9th ed.) Citation

Iurlo, A., et al. "Treatment Discontinuation Following Low-dose TKIs in 248 Chronic Myeloid Leukemia Patients: Updated Results from a Campus CML Real-life Study." Frontiers in Pharmacology, vol. 14, 2023, p. 1154377, https://doi.org/10.3389/fphar.2023.1154377.